Minnesota hospitals and clinics participating in a controversial U.S. drug discount program reaped at least $1.34 billion in revenue in 2024, and the largest institutions were the biggest beneficiaries, according to a report from the state Department of Health.
Specifically, hospitals and clinics received $3.045 billion in discounted medicines under the 340B Drug Pricing Program, but paid $1.53 billion plus another $165 million to various parties for administration fees. Meanwhile, the largest hospitals received more than $1 billion, representing 80% of the total revenue collected.
The report is the second from Minnesota, which is so far the only state to collect and analyze such data for public consumption. And it arrives as the 340B program has become a flashpoint in the debate in the U.S. over the rising cost of prescription medicines.Continue to STAT+ to read the full story…